“Higher temperatures, more flooding, rising pollution & growing population crowding … add urgency to international efforts to #StopSuperbugs by developing new medicines & by blocking the pathways through which pathogen immunity spreads.”

We CARB-X stand ready to play our part.

CARB-X is doing its part - together with many others - to respond to the pipeline and access crisis.

GLG-ESCMID panelist Dr Erin Duffy, Chief of R&D CARB-X raises awareness about the lack of researchers in #AMR impacting the development of new antibiotics. She also notes innovation must be accompanied by access and stewardship for a sustainable pipeline of #antibiotics .

At our #ESCMIDGLG event, panellist and Chief of CARB-X Dr Erin Duffy shone a light on the various crises slowing down #AMR R&D and the development of a sustainable antibiotic pipeline, including the crises of innovation, access, investment and people. #AMR #ESCMIDGlobal

'You can't have innovation if you don't have proper stewardship' responded CARB-X's Dr Erin Duffy during our #GLG event Q&A, highlighting that innovation must be accompanied by access and stewardship, if we are striving for sustainable pipeline of antibiotics. #ESCMIDGlobal #AMR

💼 CARB-X is #hiring !

We are looking for a SENIOR ALLIANCE MANAGER to help manage our portfolio that includes antibiotics, vaccines, live biotherapeutics, bacteriophage, non-traditionals & more.

➡️ Apply today: bit.ly/3JqgCNH

New funding opportunity!

FIND is seeking manufacturers of point-of-care molecular tests for gonorrhoeae & chlamydia to accelerate product development, evaluation & market entry in low- and middle-income countries.

Apply by May 6 at 23:59 CEST.

🔗bit.ly/3UoftMU

🗞️ New interview!

CARB-X Chief of R&D Erin Duffy, PhD, spoke with PharmaVoice about how CARB-X is stepping up to address the world’s greatest bacterial threats to humans.

🔗 Full article: bit.ly/3TSwxc8

#AMR #StopSuperBugs #AntibioticResistance #GlobalHealth

💼 Are you interested in using your R&D skills to tackle a global health threat?

CARB-X is #hiring an ALLIANCE DIRECTOR to help manage our prevention portfolio including vaccines, live biotherapeutics, bacteriophage, & other preventatives.

➡️ Appy today! bit.ly/3xDlWL3

📘 New publication!

CARB-X Alliance Director Ed Buurman, PhD, MBA, contributed to this article on the current state of #phage therapy , including major R&D challenges and new opportunities for #phage technology based on #AI & synthetic phage production.

🔗 bit.ly/3xpFYbt

📘 New publication!

CARB-X Chief of R&D Erin Duffy, PhD, and Alliance Director Ed Buurman, PhD, MBA, helped develop a Vaccine Value Profile for K. pneumoniae, a major cause of pneumonia, bloodstream infections, & infections in newborns.

🔗 Read more: bit.ly/3IVVs9S

Join CARB-X’s Chief Scientific Officer Richard Alm, PhD, at the World Vaccine Congress in Washington D.C., on April 1, 2024. During his talk, he will discuss Accelerating the Development of Novel Tools against AMR.

#WorldVaccineCongress #AMR

Join CARB-X’s Chief Scientific Officer Richard Alm, PhD, at the World Vaccine Congress in Washington D.C., on April 1, 2024. During his talk, he will discuss Accelerating the Development of Novel Tools against AMR.

#WorldVaccineCongress #AMR

⏰ Expressions of Interest are due tomorrow!

Submit Expressions of Interest for #preventatives , #therapies , & #diagnostics for drug-resistant bacteria by tomorrow, Mar. 29 at 23:59 ET to be considered in the first of two application cycles.

🔗 Apply: bit.ly/3P56UDB